Physician profile
Rachel Simpson
NPI 1982041372
$39,112.34
in general payments reported to CMS, 2019-2025
15 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $128 · 2021: $190 · 2022: $1,640 · 2023: $3,676 · 2024: $14K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Food and Beverage: $3,440 · Travel and Lodging: $3,414 · Long Term Medical Supply Or Device Loan: $1,039 · Entertainment: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,640.00 |
| Food and Beverage | $3,440.27 |
| Travel and Lodging | $3,414.44 |
| Long Term Medical Supply Or Device Loan | $1,038.75 |
| Entertainment | $242.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $30,107.63 | 2023-2025 | Travoprost Intraocular Implant - Idose, Idose, Istent Trabecular Micro-Bypass Stent System |
| Abbvie INC. | $3,525.13 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Alcon Vision LLC | $1,772.08 | 2023-2025 | Voyager Dslt, Clareon, Centurion |
| Nova Eye, INC. | $1,423.81 | 2023-2025 | |
| W. L. Gore & Associates, INC. | $840.00 | 2025 | Product In Development |
| New World Medical,INC. | $379.48 | 2022-2023 | |
| Allergan, INC. | $271.62 | 2019-2020 | |
| Sight Sciences, INC. | $244.40 | 2019-2024 | Omni Surgical System |
| Carl Zeiss Meditec, INC. | $189.93 | 2019-2023 | Artevo 800, Callisto Eye, Veracity Surgical |
| Aerie Pharmaceuticals, INC. | $125.42 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $115.47 | 2024 | Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $67.47 | 2023 | Envista Mx60 Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.75 | 2021 | |
| Genentech USA, INC. | $24.15 | 2024 | Avastin, Itovebi, Perjeta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.